RGNT
Regentis Biomaterials Ltd. (RGNT) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D-). The rating has held at C- for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C+ (2.5) | C+ (2.5) | D- (0.8) | D+ (1.6) | C+ (2.6) | C- (2.0) |
| 2026-11-07 | C+ (2.5) | C+ (2.5) | D- (0.8) | D+ (1.7) | C+ (2.7) | C- (2.0) |
| 2026-10-31 | C+ (2.5) | C+ (2.5) | D- (0.8) | D+ (1.6) | C+ (2.7) | C- (2.0) |
| 2026-10-24 | C+ (2.5) | C+ (2.5) | D- (0.8) | D (1.3) | C+ (2.6) | C- (2.0) |
| 2026-10-17 | C+ (2.5) | C+ (2.5) | D- (0.8) | D+ (1.5) | C+ (2.6) | C- (2.0) |